中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(7): 1608-1611

Clinical cure of the non-dominant population in chronic hepatitis B patients with HBsAg>3000 IU/mL: A report of two cases

DOI: 10.3969/j.issn.1001-5256.2022.07.027

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2017ZX10203201-002-002)

More Information
  • Corresponding author: GAN Jianhe, ganjianhe@suda.edu.cn(ORCID: 0000-0002-1288-0178)
  • Received Date: 2021-08-10
  • Accepted Date: 2021-11-01
  • Published Date: 2022-07-20
    Abstract
    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [2]
    Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
    [3]
    CHAN H, CHAN F, HUI AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study[J]. J Viral Hepat, 2019, 26(1): 126-135. DOI: 10.1111/jvh.13000.
    [4]
    HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study[J]. Chin J hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.

    胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
    [5]
    HOU JL, WEI L, WANG GQ, et al. Chinical cure of hepatitis B: consensus and controversy[J]. Chin J hepatol, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409.

    侯金林, 魏来, 王贵强, 等. 乙型肝炎临床治愈: 共识与争议[J]. 中华肝脏病杂志, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409.
    [6]
    HAN MF, WU D, TAN DM, et al. Combination/Sequential Therapy with ETV, Peg-IFN alpha-2b and GMCSF Enhanced HBsAg Loss and Appearance of HBsAb in NA Suppressed CHB Patients (the Anchor A Study): An Interim Analysis[C]. AASLD. Washington, 2017.
    [7]
    WU FP, YANG Y, LI M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL: An observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539. DOI: 10.3748/wjg.v26.i13.1525.
    [8]
    JIN Y, HUANG CY, WEI FL, et al. Combination therapy in HBeAg-positive chronic hepatitis B patients with poor virological response/HBV resistance to NAs[J]. Infect Dis Info, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.

    金怡, 黄春洋, 魏飞力, 等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究[J]. 传染病信息, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.
    [9]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [10]
    LI M, ZHANG L, LU Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon α-2a[J]. Virol Sin, 2021, 36(2): 311-320. DOI: 10.1007/s12250-020-00290-7.
    [11]
    MA Y, WANG J, XIONG F, et al. Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis[J]. Infect Genet Evol, 2020, 85: 104492. DOI: 10.1016/j.meegid.2020.104492.
    [12]
    BAO X, GUO J, XIONG F, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs[J]. Int J Infect Dis, 2020, 96: 562-566. DOI: 10.1016/j.ijid.2020.05.041.
    [13]
    LAMPERTICO P, MESSINGER D, CORNBERG M, et al. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B[J]. Ann Gastroenterol, 2018, 31(6): 712-721. DOI: 10.20524/aog.2018.0300.
    [14]
    CAO W, LI M, ZHANG L, et al. The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy[J]. Biomed Res Int, 2021, 2021: 2178143. DOI: 10.1155/2021/2178143.
    [15]
    WANG JY, LI TJ, FU H, et al. Clinical and immunological characteristics of rapid decline of HBsAg at early stage of anti-HBV treatment with peginterferon[J]. Chin J Infect Chemother, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010.

    王嘉悦, 李天驹, 付豪, 等. 聚乙二醇干扰素治疗慢性乙型病毒性肝炎早期HBsAg快速下降的临床及免疫学特征研究[J]. 中国感染与化疗杂志, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010.
    [16]
    MARCELLIN P, AHN SH, MA X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology, 2016, 150(1): 134-144. e10. DOI: 10.1053/j.gastro.2015.09.043.
    [17]
    HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α 2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/IMP3019.
    [18]
    SUN J, DING H, CHEN G, et al. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China[J]. BMC Gastroenterol, 2019, 19(1): 65. DOI: 10.1186/s12876-019-0981-5.
    [19]
    LEE SK, KWON JH, LEE SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294. DOI: 10.1111/liv.14701.
    [20]
    REN P, CAO Z, MO R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18(10): 1085-1094. DOI: 10.1080/14712598.2018.1518423.
    [21]
    LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24(Suppl 1): 12-20. DOI: 10.1111/jvh.12755.
    [22]
    DONG Y, LI M, ZHU S, et al. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis[J]. J Viral Hepat, 2020, 27(12): 1338-1343. DOI: 10.1111/jvh.13372.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (773) PDF downloads(69) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return